Quantum Biopharma three-month net loss narrows 90% year over year to USD 474,279 for period ended September 30, 2026
QNTM•Quantum Biopharma’s net loss narrowed 90% year over year to USD 474,279 for the three months ended September 30, 2026. Operating expenses fell 24% to USD 3.56 million, while cash used in operating activities declined 21% to USD 6.25 million for the first nine months.
1. Quarterly results
Quantum Biopharma’s net loss narrowed 90% year over year to USD 474,279 for the three months ended September 30, 2026. Total operating expenses fell 24% to USD 3.56 million. For the nine months ended September 30, cash used in operating activities declined 21% to USD 6.25 million.
